Chapter 79: Drugs Affecting Calcium Levels and Bone Mineralization

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we think about the human skeleton, we picture this permanent rock solid framework, like the steel girders of a skyscraper.

It's just kind of there holding everything else up.

Right, yeah.

It feels completely static,

unchanging.

But when you start looking at the pharmacology of bone health,

that whole skyscraper metaphor completely collapses

because the body doesn't treat the skeleton like structural steel at all.

No, not even a little bit.

It treats it like a bank account.

And the wild part is the body cares so much about having enough calcium in the bloodstream to keep your heart beating and your nerves firing that it will literally bulldoze your skeleton to get it.

It's honestly, it's one of the great physiologic ironies.

The preservation of blood calcium takes absolute priority over the structural integrity of your bones every single time.

So if you are prepping to hit the clinical floor or maybe staring down a massive pharmacology exam,

this dynamic is exactly what we are unpacking today.

We're doing a deep dive into lens pharmacology for nursing care, specifically chapter 79,

focusing entirely on drugs affecting calcium levels and bone mineralization.

And we are going to translate all that dense textbook drug info into the clinical reality of how the body manages this bank account and what happens when we use medications to intervene.

But to understand those interventions, we have to understand the currency first.

So calcium.

Yeah, calcium is doing a lot of heavy lifting.

It's critical for the skeletal, nervous, muscular and cardiovascular systems,

but 98 % of it is locked away in the bone.

Wow, 98%.

So because it's locked in the bone, the body has to constantly remodel it to make withdrawals or deposits.

When we think about bone remodeling, it's really like repaving a highway.

That's a great way to look at it.

You have two main crews working.

First, the osteoclasts.

These are the bulldozers.

Their job is bone resorption.

They rip up the old bone to release calcium into the blood.

Then you have the osteoblasts.

These are the paving machines.

They take calcium from the blood and lay down new bone matrix, which is deposition.

And keeping those bulldozers and paving machines supplied requires constant raw materials.

The daily requirements for calcium actually fluctuate throughout life.

It's not just a flat rate.

No, interestingly, the peak requirements aren't for adults.

They are for adolescents between nine and 18 years old.

They need about 1 ,300 milligrams a day to build that initial bone mass.

Makes sense, they're growing so fast.

Exactly.

Then it drops a bit for younger adults and then climbs right back up for women over 50 and all adults over 70.

But we also have to highlight a major safety alert here because there's this really common assumption that, well, if some calcium is good, taking massive amounts of over -the -counter supplements must be better.

Oh yeah, and that is fundamentally incorrect.

Pushing calcium far beyond the recommended dietary allowance is genuinely dangerous.

Why is that?

Because when the blood becomes super saturated, that excess calcium has to go somewhere.

It ends up depositing in soft tissues.

You drastically increase the risk of vascular calcification, which can lead to myocardial infarction and stroke.

Not to mention, you know, agonizing kidney stones.

Ouch.

So the body desperately wants to keep this in a tight, auto -regulated window.

And there are really three heavy hitters regulating this blood calcium balance.

We've got parathyroid hormone or PTH, vitamin D, and calcitonin.

And they operate on a very strict hierarchy.

PTH and vitamin D are the two that raise blood calcium levels.

Okay.

So when levels drop, the parathyroid gland senses it and releases PTH.

PTH essentially sounds the alarm.

It activates the osteoclast bulldozers to pull calcium out of the bone.

So it's a making -or -draw.

Exactly.

And it also signals the kidneys to stop excreting calcium in the urine, and it activates vitamin D, which in turn dramatically increases how much calcium you absorb from your diet and the gut.

Got it.

Then we have the opposite mechanism, calcitonin acting as the brakes.

When blood calcium gets too high, the thyroid gland releases calcitonin.

It steps in, shuts down the bulldozers, and tells the kidneys to dump more calcium into the urine.

That's the perfect balance.

But clinically, you're gonna see a lot of patients where that delicate regulation fails.

Let's look at what happens when there is too much calcium in the blood hypercalcemia.

A lot of times, this is asymptomatic, but when it's severe, it's usually driven by cancer or an overactive parathyroid gland.

Yeah, and the symptoms are systemic.

Because calcium affects nerve and muscle excitability, too much of it acts like a depressant.

So things slow down.

Exactly.

You see lethargy, profound weakness, kidney damage as the body tries to filter it out, and dangerous cardiovascular dysrhythmias.

Or on the flip side, hypercalcemia to little calcium makes the neuromuscular system incredibly excitable.

Yes, because without enough calcium to stabilize the cell membranes, nerves just fire spontaneously.

This leads to tetany, severe muscle spasms, and even convulsions.

Beyond just the blood levels, we also see disorders in the actual highway repainting process itself, like Paget's disease.

Paget's is a prime example.

This isn't a systemic lack of calcium.

It's abnormal localized bone remodeling.

So the crews are just messing up in one spot.

Right.

In Paget's disease, the bulldozers and paving machines go into absolute overdrive in very specific spots, often the pelvis, spine, or skull.

Wow.

They are tearing down and rebuilding bones so fast that the new bone is completely disorganized.

It's laid down haphazardly.

So it's not stronger.

Not at all.

It results in bones that are enlarged, but structurally weak, and highly prone to deformity and fracture.

We also see issues with the managers of the site, the parathyroid glands.

Yes.

Primary hyperparathyroidism is usually straightforward.

It's a benign tumor on the gland just pumping out too much PTH, driving blood calcium up.

But secondary hyperparathyroidism is something you'll see constantly in patients with chronic kidney disease, especially those on dialysis.

The link there is crucial to understand for nursing students.

It really is.

Remember that the kidneys are responsible for activating vitamin D and excreting phosphorus.

In chronic kidney disease, those functions fail.

So phosphorus levels rise, which binds up the free calcium in the blood, dropping calcium levels.

The parathyroid gland senses this chronic low calcium and goes into overdrive, constantly pumping out PTH to try and fix it.

But it can't fix it.

No, it can't.

So over time, the glands physically enlarge and refuse to shut off, constantly robbing the bones of calcium.

Which brings us to the actual pharmacology.

How do we treat all this?

Let's start with the most basic intervention.

Calcium salts.

Good place to start.

These come in both oral and IV formulations.

Oral calcium like calcium carbonate or calcium citrate is standard for mild deficiencies.

But if you're managing a patient's med pass, you have to be incredibly careful because oral calcium interacts with almost everything.

It really does.

And it all comes down to binding.

In the GI tract, calcium is a bulky, highly reactive mineral.

So what happens if you mix it?

Well, if you give it at the same time as certain antibiotics, like tetracyclines or fluoroquinolones, the calcium physically binds to the antibiotic in the stomach.

Yeah, it creates this heavy complex that the body cannot absorb.

You end up rendering the antibiotic completely useless.

It also binds to and blocks the absorption of thyroid hormones and the anticonvulsant finitoin.

Not to mention food interactions.

Things like spinach, which contains oxalic acid, or bran, which has phytic acid, will bind the calcium right in the gut.

Exactly, so timing is everything.

You have to space these meds out.

Now, what if the patient is in severe hypocalcemic tetany?

We aren't waiting for a pill to digest.

We're giving IV calcium, usually calcium gluconate.

And the nursing safety alerts here are massive.

First, the solution must be warmed to body temperature.

Second, it has to be pushed incredibly slowly.

Let's explain why, because it's a high -stakes scenario, especially if the patient is taking digoxin for heart failure.

Right, so digoxin works by increasing intracellular calcium in the heart muscle to strengthen the contraction.

If you rapidly push IV calcium into a patient already on digoxin, you cause a massive sudden spike in cardiac calcium.

This can trigger severe fatal bradycardia or dysrhythmias.

That is terrifying.

It is.

Furthermore, if you are using IV calcium chloride instead of gluconate, it is highly irritating to the veins.

If the IV line infiltrates and that calcium leaks into the surrounding tissue, it acts as a caustic agent.

Oh, no.

Yeah, causing severe tissue necrosis and slipping.

It's a huge deal.

So we have ways to supplement calcium safely if we follow the rules,

but what if we need to rein in that overactive parathyroid gland we talked about earlier, especially in our kidney disease patients?

That's where we use a drug called Cynocalcid.

Cynocalcid.

Yeah, and it's fascinating.

It's part of a class called calcimimetics.

It doesn't destroy the parathyroid gland or block the hormone directly.

So what does it do?

It targets the calcium -sensing receptors on the parathyroid gland itself.

It physically increases the sensitivity of those receptors.

So even if blood calcium is normal or slightly low, the gland is tricked into thinking there is plenty of calcium around.

Oh, I see.

Which suppresses the release of PTH.

So we're effectively altering the thermostat.

That makes perfect sense.

Now let's move to vitamin D.

A really surprising takeaway from chapter 79 is that vitamin D acts much more like a hormone than a traditional vitamin.

It really does.

I mean, a vitamin is typically something we must get entirely from our diet because our bodies can't make it.

Right, like vitamin C.

Exactly.

But under ideal conditions with enough sunlight, we synthesize vitamin D ourselves in the skin.

The catch is that it starts off completely inactive.

Right, it has to go on a whole systemic journey.

Whether you get it from the sun or from an oral supplement like colcalciferol, which is vitamin D3 in the preferred clinical form, it first has to travel to the liver where it gets converted into calcifedial.

Then it has to travel to the kidney to be fully activated into calcitriol.

If any part of that chain is broken like in severe liver or kidney failure,

the vitamin D is just useless.

And just like with calcium, we have to talk about toxicity.

Hypervitaminosis, D is dangerous.

Because it forces calcium absorption.

Exactly.

The excess vitamin D forces the gut to absorb massive amounts of calcium, leading to severe hypercalcemia.

And there is a bizarre paradox here.

This is where that more is better myth that really falls apart.

You would think massive amounts of vitamin D would give you bones of steel.

You'd think so, but it's exactly the opposite.

At toxic levels, once the blood is saturated, the body starts depositing that calcium into soft tissues, damaging the heart, blood vessels, and lungs.

But to keep those blood levels high, toxic doses of vitamin D will actually trigger bone detoxification.

It will actively pull calcium out of the bones to keep the blood levels dangerously elevated.

That is wild.

Oversupplementing literally dissolves the bone it's supposed to protect.

Exactly.

Now what about our other natural regulator, calcitonin?

When we give this pharmacologically, we don't actually use human calcitonin.

We use calcitonin salmon.

Why salmon?

It's purely about pharmacokinetics.

The salmon -derived version has a much longer half -life and significantly higher milligram potency than the human version.

So it just works better.

Way better.

It's highly effective at doing what natural calcitonin does, inhibiting those osteoclast bulldozers.

We use it to treat osteoporosis, Paget's disease, and sometimes emergency hypercalcemia.

And it's generally given by injection or a nasal spray, right?

The nasal spray comes with some serious caveats.

It does.

Intranasal calcitonin is convenient, but it was actually pulled from the Canadian market back in 2013.

Wow, really?

Yeah, because clinical trials showed a slight, but statistically significant, increased risk of malignancy with long -term use.

That's a big deal.

It is.

It is still available in the U .S., but the FDA recommends carefully weighing the risks, and clinical guidelines generally don't consider it a first -line jade anymore.

So if calcitonin isn't our first -line defense anymore, what is?

That brings us to the heavy hitters, the bisphosphonates.

Ah.

So if you're looking at a med list for a patient with osteoporosis, you're almost guaranteed to see alendronate, brand name Fosamax.

Yes.

And the mechanism here is honestly mind -blowing.

It really is.

Most drugs bind to a receptor, do their job, and wash out of the system.

Bisphosphonates physically incorporate themselves permanently into the bone matrix.

Permanently.

Yes.

They become part of the bone tissue itself, sometimes for years or even decades.

So how does that stop bone loss?

When the osteoclast bulldozers come along to absorb that bone, they ingest the bisphosphonate along with the calcium.

Once inside the osteoclast, the drug acts like a poison.

It essentially paralyzes the cell from the inside, completely shutting down bone resorption.

It's like mixing concrete with something that breaks the bulldozer's engine.

That is exactly what it does.

But for the nursing student looking at the administration protocol for alendronate, the rules are insanely rigid.

You can't just hand this to a patient with their morning breakfast tray.

Absolutely not.

And the reasoning is all about cause and effect.

First, the bioavailability of alendronate is microscopic.

It's just 0 .7%.

Wow, less than 1%.

Yeah, less than 1 % of the pill actually makes it into the bloodstream under the best conditions.

If you take it with solid food, absorption drops to zero.

If you take it with milk or juice, zero.

Even a cup of coffee ruins it.

So rule one,

it must be taken first thing in the morning on a completely empty stomach with a full glass of plain water.

And rule two is even more critical for safety.

The patient has to stay completely upright for at least 30 minutes.

Why?

This goes back to how caustic the drug is.

If the pill gets stuck in the esophagus or if the patient lies down in the medication refluxes, prolonged contact with the esophageal mucosa can cause severe ulceration.

Oh, that sounds awful.

It is.

It can lead to bleeding and even perforation.

If a patient is bed bound or physically cannot sit or stand upright for 30 minutes, this drug is absolutely contraindicated.

That's a perfect example of knowing why a protocol exists so you don't accidentally harm a patient.

Exactly.

But even when taken perfectly, shutting down these bulldozers so completely comes with some really bizarre, terrifying long -term risks.

They are rare but severe.

One is osteonecrosis of the jaw or ONJ.

This is mostly seen with the IV forms of dysphosphonates.

It's exactly what it sounds like, localized bone death in the jaw.

What triggers that?

It's almost always triggered by an invasive dental procedure like a tooth extraction.

The bone can't heal itself and it dies.

And the other major concern is atypical femur fractures, which sounds like a contradiction.

I mean, we are giving a drug to prevent bone fractures, but it can actually cause them.

Yes, and it has to do with the total paralysis of bone remodeling.

Our bones get tiny microcracks in them every single day just from walking around.

Sure.

Normally osteoclasts clear out those cracks and osteoblasts repair them.

Because dysphosphonates shut down the osteoclasts so completely, that repair process stops.

Oh, I see where this is going.

Yeah.

Over years and years, those microcracks accumulate.

The bone might look dense on a scan, but it's brittle.

Eventually, the femur can just snap with almost no trauma at all.

Which is why there's a big push now to reevaluate whether patients really need to stay on these drugs after five years.

Exactly right.

You also have to watch out for specific patient populations.

Dysphosphonates cross the placenta and cause fetal harm in animal studies, so they are avoided in pregnancy.

And if you are giving the IV forms, like zooledronate, there are major safety alerts.

Correct.

Four dysphosphonates are classified by Neodush as hazardous drugs requiring special handling.

Okay.

Furthermore, because they are given IV, they carry a high risk of dose -dependent kidney damage.

You must monitor creatinine clearance closely, ensure the patient is well hydrated, and infuse it very slowly to protect the nephrons.

Now, shifting gears from dysphosphonates, we have to talk about hormone therapies.

Historically, giving postmenopausal women estrogen was the go -to for preventing bone loss, because estrogen naturally puts the brakes on osteoclasts.

Right.

But over time, the clinical data showed the side effects, an increased risk of breast cancer, myocardial infarction, stroke.

They were just too high.

That clinical dilemma led to the development of the CIRMS, or selective estrogen receptor modulators, like Riloxafine.

Yes.

The brilliance of CIRMS is right in the name.

Selective.

They are designed to give you the benefits of estrogen in certain tissues without the drawbacks in others.

So how does Riloxafine pull that off?

Well, in the bones, Riloxafine acts exactly like estrogen.

It binds to the receptors and preserves bone density, preventing fractures.

But in the breast and the uterus, it acts as an anti -estrogen.

It blocks the receptors, which actually protects against estrogen receptor positive breast cancer.

Wait, so it builds up the bone defenses while actively blocking cancer pathways in the breast.

That's incredible.

It is highly effective, but it's not without risk.

Riloxafine carries a black box warning for deep vein thrombosis, or DVT, and pulmonary embolism.

There's always a catch.

Always.

It increases the coagulability of the blood, similar to traditional estrogen.

So patients have to discontinue the drug 72 hours before any situation involving prolonged demobilization.

Like a major surgery or a long flight.

Exactly, and it is strictly contraindicated in pregnancy.

Got it.

Now up to this point, every single drug we've talked about,

calcitonin, bisphosphonanes, estrogen, Riloxafine, they all share one massive limitation.

They only stop the bulldozers.

Right, they just prevent further bone loss.

None of them actually build new bone.

Until we look at terapeurotide.

Terapeurotide, brand name Fortio, is unique.

It is the first and currently only approved drug that actively builds new bone.

But wait, it's actually a recombinant, manmade form of parathyroid hormone, right?

Yes, it is.

But earlier we said parathyroid hormone breaks down bone to raise blood calcium.

How is a synthetic version building bone?

It's all about how it's administered.

When the body constantly pumps out PTH, like in hyperparathyroidism, it breaks down bone.

But terapeurotide is given as a once daily subcutaneous injection.

This creates a very brief transient spike in PTH levels in the blood.

And for reasons we don't entirely understand, transient spikes in PTH don't stimulate the bulldozers.

They preferentially stimulate the osteoblasts, the paving machines, to lay down brand new, structurally sound bone matrix.

So unlike everything else we've discussed that just stops the bulldozers, this actually builds new roads.

Precisely, but there are significant catches.

Of course.

It requires a daily injection.

It must be kept strictly refrigerated in a special pre -filled pen that expires 28 days after the first use.

It is wildly expensive.

And crucially, it carries a black box warning for osteosarcoma, a form of bone cancer, which was observed in animal studies.

So you would absolutely avoid giving this to a patient who already has an elevated risk for bone cancer, like someone with Paget's disease or someone who has had radiation therapy to their bones.

Exactly, it's a powerful tool, but reserved for patients with severe osteoporosis who are at exceptionally high risk for fractures.

We also have the monoclonal antibodies, specifically dinosumab.

This is categorized as a anankal inhibitor.

Walk us through how this works because it's a completely different pathway.

Yeah, so anankal is essentially the chemical activation signal sent to osteoclasts, telling them to mature and start resorbing bone.

Dinosumab is an antibody that physically intercepts that signal in the bloodstream.

Okay, so it stops the message.

It binds to anankal before it can ever reach the osteoclast.

By intercepting the orders, it starves the osteoclasts of their activation, and they just shut down.

It's literally cutting the radio wire to the bulldozers.

Exactly, but because it's so incredibly effective at stopping bone breakdown, it carries a massive risk for severe hypocalcemia.

Because the bone isn't releasing any calcium at all.

Right, blood levels can just plummet.

Patients must take daily calcium and vitamin D alongside it.

Dinosumab also carries a risk of serious infections because reNKL is also involved in immune system function.

Right.

And similar to bisphosphonates, it carries the risk for osteonecrosis of the jaw.

Just to quickly round out the drug classes, if you have a patient in a hypercalcemic emergency, say their calcium is dangerously high due to a malignancy, the immediate protocol relies on flushing it out and locking it down.

Yes, we use IV disphosphonates like ziladrinate to immediately lock the remaining calcium in the bone.

We use calcitonin to force the kidneys to excrete it.

Glucocorticoids to stop the gut from absorbing anymore.

And sometimes the loop diuretic furosemide to rapidly flush it out through the urine.

That combination attacks the hypercalcemia from every single physiological angle.

All right, so we've covered the physiology and the pharmacology.

Let's put this into clinical practice with the final focus of the text osteoporosis.

This disease is responsible for 1 .5 million fractures a year.

But how do we actually diagnose it before a fracture happens?

We use two main clinical decision tools.

First is the FRAX tool.

This is a calculator that estimates a patient's 10 -year risk of a major osteoporotic fracture based on factors like age, weight, medical history, and medication use.

And the second one.

Second, and more definitively, is the DxA scan, which measures bone mineral density.

And the DxA scan gives the provider a T -score.

To translate this for you, a T -score simply compares your bone density to that of a healthy young adult.

Down to a minus one is considered normal.

Between minus one and minus 2 .5 means you have osteopenia.

You're losing bone mass, but you haven't crossed the threshold yet.

But a T -score of minus 2 .5 or lower.

That is the official diagnostic criteria for osteoporosis.

And when looking at risk, we have to look at how this disease affects women versus men.

Women experience an accelerated, steep phase of bone loss for several years immediately following menopause.

And this is driven entirely by the sudden drop in protective estrogen.

Exactly.

But men don't have that sudden menopausal drop, so why do they eventually get osteoporosis too?

Because aging affects us all.

Men lose bone at the exact same slow, steady rate as women do as they age.

Okay.

However, men generally start with larger, denser bones.

They simply have a much larger starting balance in their bone bank account.

The bank account account.

Yeah.

So as they lose it at that slow rate, it takes them much longer to hit that fragile minus 2 .5 fracture threshold.

But when they do hit it, the risk of a fatal fracture is just as high.

And the treatment foundation for both groups is exactly the same.

Ensure adequate calcium and vitamin D, engage in weight -bearing exercises to physically stimulate bone density, and use these entire sorts of drugs we've discussed to slow the drain on the account.

It is a beautifully complex system, but incredibly logical once you see how each drug specifically manipulates the body's natural pathways.

It really is.

But looking at the big picture, it does leave us with a profound clinical dilemma.

This raises an important question.

What's that?

We spend our entire lives relying on these osteoclast bulldozers to tear down old bone, not just to keep our blood calcium stable, but to heal the micro -fractures of daily life.

Right.

When we prescribe powerful drugs that paralyze these cells for decades in order to treat osteoporosis, are we truly curing the disease?

Or are we simply trading age -related brittle bones for pharmacologically frozen bones that might eventually shatter in completely new atypical ways?

Wow.

That is absolutely a lingering thought to chew on as you study.

You can't just stop the body's bulldozers forever without consequences.

To you, our listener, whether you're heading into a massive pharmacology exam or stepping onto the clinical floor to manage these very meds, you are now armed with the why behind the what.

Keep questioning the mechanisms, keep learning.

And from the last -minute lecture team, thank you for joining us on this deep dive.